Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal
solutions company, today announced the commercial launch of the
ADIRA™ XLIF™ Plate System, the Company’s first product launch
compatible across its expanded lateral interbody portfolio.
“This launch represents an important milestone in our
integration roadmap,” said David Hole, president of Spine
at Globus Medical. “Through the system’s ability to be paired
with our industry-leading Globus and NuVasive interbody spacers,
ADIRA™ demonstrates our continued commitment to accelerated
procedural innovation in lateral spine surgery.”
The ADIRA™ XLIF™ Plate System refines lateral plating by
offering simplified insertion workflows and a rigid coupling
mechanism to confidently align plates over interbody spacers to
enhance construct stability. Compatible with bone screws and
lateral MIS anchors, the ADIRA™ XLIF™ Plate System offers
procedural versatility for bone fixation options as well as
interbody spacer types.
“This system provides both efficiency and confidence in cases
that require stand-alone or supplemental lateral plating,” said Dr.
Anthony Bozzio, MD, Bay Street Orthopaedics & Spine. “Whether
attaching the plate in situ or on the back table for static
single-construct insertion, the system provides me with
streamlined, rigid plate-interbody connection.”
Procedurally integrated throughout the Globus Medical lateral
portfolio, ADIRA™ plates are designed to rigidly thread into
RISE-L™, Modulus™ XLIF™, Hedron L™, Cohere™ XLIF™,
TransContinental™, and CoRoent™ XLIF™ interbody spacers, to help
reduce the risk of spacer migration while accommodating varied
patient anatomy and surgeon preferences.
ADIRA™ Plate-Spacer Assemblies and FDA Cleared
Indications ADIRA™ plates may be assembled to lateral
lumbar interbody fusion devices (HEDRON L™, TransContinental™,
RISE-L™, Modulus™ XLIF™, Cohere™ XLIF™, or CoRoent™) with an
alignment screw to create an ADIRA™ Plate-Spacer assembly, to
provide structural stability in skeletally mature individuals
following discectomy. The plate-spacer assembly is used with bone
screws and/or lateral anchors.
ADIRA™ Lateral Plate SystemThe ADIRA™ 2-Hole and 4-Hole Plates,
when used with screws only, are intended for use in the treatment
of thoracolumbar (T1-L5) spinal instability as a result of fracture
(including dislocation and subluxation), tumor, degenerative disc
disease (DDD, defined as back pain of discogenic origin with
degeneration of the disc confirmed by patient history and
radiographic studies), scoliosis, kyphosis, lordosis, spinal
stenosis, or failed previous spinal surgery.
The ADIRA™ 1-Hole Plate is intended to stabilize allograft or
autograft at one level (T1-L5), aiding in spinal fusion and to
provide temporary stabilization and augment development of a spinal
fusion. It may be used alone or with other anterior, lateral,
anterolateral, or posterior spinal systems. The device is not
intended for load bearing applications.
ADIRA™ Plate-Spacer AssembliesADIRA™ Plates may be assembled to
a lateral lumbar interbody fusion device (HEDRON L™,
TransContinental™, RISE-L™, Modulus™ XLIF™, CoRoent™, or Cohere™
XLIF Spacers) to create a plate-spacer assembly. When assembled to
HEDRON L™, TransContinental™, or RISE-L™ Spacers, the plate-spacer
assembly is indicated for use at one or more levels of the
lumbosacral spine (L1-L5), as an adjunct to fusion in patients with
the following indications: degenerative disc disease (DDD), disc
herniation (with myelopathy and/or radiculopathy),
spondylolisthesis, deformity (degenerative scoliosis or kyphosis),
spinal stenosis, and failed previous fusion (pseudarthrosis). DDD
is defined as discogenic back pain with degeneration of the disc
confirmed by history and radiographic studies. These patients
should be skeletally mature and have had at least six (6) months of
non-operative treatment. When ADIRA™ Plates are assembled to
Modulus™ XLIF™, CoRoent™, or Cohere™ XLIF™ Spacers, the
plate-spacer assembly takes on the indications of the interbody
device.
ADIRA™ Plate-Spacers are intended to be used with screws and/or
anchors which accompany the implants. These devices are intended
for use with supplemental fixation (e.g. facet screws or posterior
fixation). In addition, the 2-Hole or 4-Hole Plate-Spacers are
intended for stand-alone use in patients with DDD at one or two
levels only when <20° lordotic implants are used with two or
four screws, respectively.
ADIRA™ Plate-Spacers are to be filled with autograft and/or
allogenic bone graft comprised of cancellous and/or
corticocancellous bone.
About Globus Medical, Inc.Globus Medical is a
leading musculoskeletal company based in Audubon, PA, relentlessly
focused on developing technologies, procedures and products that
solve unmet clinical needs, promote healing in patients, and change
lives around the globe. Additional information can be accessed at
www.globusmedical.com.
Safe Harbor Statements All statements
included in this press release other than statements of historical
fact are forward-looking statements and may be identified by their
use of words such as “believe,” “may,” “might,” “could,” “will,”
“aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,”
“plan” and other similar terms. These forward-looking statements
are based on our current assumptions, expectations and estimates of
future events and trends. Forward-looking statements are only
predictions and are subject to many risks, uncertainties and other
factors that may affect our businesses and operations and could
cause actual results to differ materially from those predicted.
These risks and uncertainties include, but are not limited
to, the risks and costs associated with the integration of,
and the ability of Globus Medical and NuVasive to integrate, their
businesses successfully and to achieve anticipated synergies,
health epidemics, pandemics and similar outbreaks, including the
COVID-19 pandemic, factors affecting our quarterly results,
our ability to manage our growth, our ability to sustain
our profitability, demand for our products, our ability to
compete successfully (including without limitation our ability to
convince surgeons to use our products and our ability to attract
and retain sales and other personnel), our ability to rapidly
develop and introduce new products, our ability to develop and
execute on successful business strategies, our ability to comply
with laws and regulations that are or may
become applicable to our businesses, our ability to safeguard
our intellectual property, our success in defending legal
proceedings brought against us, trends in the medical device
industry, general economic conditions, and other risks. For a
discussion of these and other risks, uncertainties and other
factors that could affect our results, you should refer to the
disclosure contained in our most recent annual report on Form 10-K
filed with the Securities and Exchange Commission, including the
sections labeled “Risk Factors” and “Cautionary Note Concerning
Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and
other filings with the Securities and Exchange Commission. These
documents are available at www.sec.gov. Moreover, we operate
in an evolving environment. New risk factors and uncertainties
emerge from time to time and it is not possible for us to predict
all risk factors and uncertainties, nor can we assess the impact of
all factors on our business or the extent to which any
factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Given these risks and uncertainties, readers are
cautioned not to place undue reliance on any forward-looking
statements. Forward-looking statements contained in this press
release speak only as of the date of this press release. We
undertake no obligation to update any forward-looking statements as
a result of new information, events or circumstances or other
factors arising or coming to our attention after the date
hereof.
Investor contact:Brian
Kearns610-930-1800investors@globusmedical.com
Media contact:Moran
Chavezmedia@globusmedical.com
Grafico Azioni Globus Medical (NYSE:GMED)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Globus Medical (NYSE:GMED)
Storico
Da Gen 2024 a Gen 2025